http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111249465-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-91215 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6851 |
| filingDate | 2020-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111249465-B |
| titleOfInvention | Application of TOPK as cervical cancer cisplatin resistance treatment target |
| abstract | The invention belongs to the field of anti-cervical cancer drugs, and particularly relates to application of TOPK as a drug-resistant prevention and treatment target of cervical cancer cisplatin. In the prior art, no research is found on the relationship between TOPK and cervical cancer proliferation and cisplatin resistance. In order to define the cisplatin resistance mechanism of a cervical cancer patient and provide a better therapeutic drug for the cervical cancer patient, the invention carries out a series of researches on the influence of TOPK on the cervical cancer proliferation and the cisplatin resistance. The result shows that TOPK is highly expressed in the tissues of the cervical cancer patients; TOPK promotes the proliferation of cervical cancer cells; TOPK overexpression promotes the resistance of cervical cancer cells to cisplatin. Further research shows that the TOPK specific inhibitor OTS514 can obviously inhibit the proliferation of cervical cancer cells in vivo and in vitro, and the TOPK inhibitor OTS514 and cisplatin are combined to be applied to the treatment of the cervical cancer, so that the treatment effect is better than that of the sole cisplatin. |
| priorityDate | 2020-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.